Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STOPGAP: IP Paclitaxel in Gastric/GEJ Cancer Peritoneal Carcinomatosis
NCT04762953Phase 2Active, not recruiting
- Sponsor
- University of California, Irvine
- Start
- Feb 2021
- Primary completion
- Dec 2026
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of Paclitaxel Micelles for Injection in gastric cancer (GC), gastroesophageal junction adenocarcinoma, sponsored by University of California, Irvine. Started Feb 2021; status: active, not recruiting.
02
Drugs
Paclitaxel Micelles for Injection
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT04762953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04762953.